alexa Treating Hyperinsulinemia with Momordica charantia
ISSN: 2167-0943

Journal of Metabolic Syndrome
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Treating Hyperinsulinemia with Momordica charantia

Frank Comhaire*
Department of Endocrinology, Ghent University Hospital, Belgium
Corresponding Author : Prof. Frank Comhaire
Brakelmeersstraat, 18 B9830 Sint Martens-Latem, Belgium
Tel: +32 475 618 555
E-mail: [email protected]
Received: May 15, 2015; Accepted: June 30, 2015; Published: July 5, 2015
Citation: Comhaire F (2015) Treating Hyperinsulinemia with Momordica charantia. J Metabolic Synd 4:177. doi:10.4172/2167-0943.1000177
Copyright: © 2015 Comhaire. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Objectives: To assess the efficacy of a novel nutraceutical mainly containing the extract of bitter gourd (Momordica charantia) and α-lipoic acid for the treatment of patients with hyperinsulinemia.

Methods: Pilot prospective open-label cohort trial including 11 patients with hyperinsulinemia due to insulin resistance. The concentrations of insulin, C-peptide, glucose, haemoglobin A1c, total cholesterol, triglycerids, gamma- glutamyltransferase, and C-reactive protein were measured in blood take between 3 and 4 hours after dinner.

Results: One and 4 months after initiation of treatment there was a significant decrease of the concentrations of Insulin (to average 25% of initial value), C-peptide (to average 44% of initial value), glucose, hemoglobin A1c and gamma-glutamyl transpeptidase. Clinical significance: Treatment of patients with hyperinsulinemia, with or without diabetes or metabolic syndrome, using a novel nutraceutical containing Momordica charantia and α-lipoic acid dramatically reduced insulin resistance and may have improved non-alcoholic fatty liver disease.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version